サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1748677

結合組織病治療市場：疾患別、薬剤別、流通チャネル別、国別、地域別：産業分析、市場規模、市場シェア、予測（2024年～2032年）

Connective Tissue Disease Treatment Market, By Disease, By Drug, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 303 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.35円
結合組織病治療市場：疾患別、薬剤別、流通チャネル別、国別、地域別：産業分析、市場規模、市場シェア、予測（2024年～2032年）
出版日: 2025年06月04日
発行: AnalystView Market Insights
ページ情報: 英文 303 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

結合組織病治療の市場規模は2024年に241億6,910万米ドルとなり、2024年から2032年にかけてCAGR 5.89%で拡大

結合組織病治療市場 - 市場力学

自己免疫疾患の有病率の上昇

関節リウマチ、狼瘡、強皮症などの自己免疫疾患の罹患率の増加は、結合組織病治療市場の主要な促進要因です。世界的にこれらの慢性疾患と診断される人が増えるにつれて、効果的な治療オプションに対する需要は増加の一途をたどっています。人口の高齢化、認知度の向上、診断能力の向上は、早期発見と治療開始に寄与しています。このような患者数の急増により、製薬会社は生物学的製剤や標的免疫抑制剤などの新規治療薬の研究開発に投資せざるを得なくなっています。その結果、この動向が市場の成長を促し、高度な治療ソリューションの利用可能性を拡大しています。

結合組織病治療市場 - 主要洞察

弊社の調査アナリストによると、世界の結合組織病治療市場は、2024年から2032年にかけて約5.89%のCAGRで開発される見込みです。

疾患別では、2023年に関節リウマチ（RA）カテゴリーが市場を独占しています。

薬剤別では、2023年に最も収益を上げたのはバイオ医薬品セグメントでした。

地域別では、2023年に北米が最も高い収益を上げた地域でした。

結合組織病治療市場 - セグメンテーション分析：

世界の結合組織病治療市場は、疾患、薬剤、流通チャネル、地域のカテゴリーに分類される。

結合組織病治療市場は、疾患タイプ別にいくつかの主要セグメントに分類されます。関節リウマチ（RA）、全身性エリテマトーデス（SLE）、強皮症、多発性筋炎、皮膚筋炎、シェーグレン症候群、混合結合組織病（MCTD）、未分化結合組織病（UCTD）、その他の結合組織病などです。各疾患には、免疫抑制剤、生物学的製剤、症状管理戦略など、それぞれに合った治療アプローチが必要です。なかでも関節リウマチ（RA）は、その有病率の高さと患者のQOLに与える影響の大きさから、圧倒的なシェアを占めています。RAは、生物学的製剤や疾患修飾性抗リウマチ薬（DMARDs）の進歩により、有効性と患者の転帰が改善され、市場需要の大部分を牽引しています。RAの罹患率の上昇と治療オプションの絶え間ない革新が相まって、同市場における主導的地位は揺るぎないものとなっています。

結合組織病治療市場は、薬剤の種類によって医薬品とバイオ医薬品に区分されます。医薬品には主に、非ステロイド性抗炎症薬（NSAIDs）、コルチコステロイド、免疫抑制薬などの伝統的な薬剤が含まれ、炎症の抑制や症状の管理に役立ちます。バイオ医薬品には、モノクローナル抗体、標的治療薬、その他疾患の進行や免疫系の反応を修正することを目的とした高度な生物学的治療薬などの生物学的製剤が含まれます。中でも、複雑な自己免疫疾患の治療において優れた効果を発揮する生物学的製剤が市場を独占しています。特に関節リウマチやループスなどの疾患における生物学的製剤の台頭は、治療パラダイムに革命をもたらし、患者により個別化された効果的な治療を提供しています。バイオ医薬品は、継続的な研究、新薬の承認、患者の転帰改善に支えられ、市場の成長を牽引し続けています。

結合組織病治療市場 - 地理的洞察

結合組織病治療市場は、北米、アジア太平洋、ラテンアメリカ、欧州、中東・アフリカの各地域に分布しています。これらの地域は、ビジネスをもたらしている国に基づいてさらに分割されます。

北米は、関節リウマチ、ループス、強皮症のような自己免疫疾患の高い有病率によって、結合組織病治療市場の支配的な地域です。特に米国は、高度なヘルスケアインフラ、早期診断、これらの疾患に罹患しやすい高齢化により、大きな市場シェアを占めています。また、この地域には大手製薬企業やバイオ医薬品企業が存在し、新しい治療法の研究開発に多額の投資を行っていることも利点となっています。さらに、有利な償還政策や自己免疫疾患に関する認知度の向上も市場の成長に寄与しています。革新的な生物製剤や免疫抑制剤への需要がこの地域の優位性をさらに加速させ、市場規模と治療法の進歩の両面でリーダー的存在となっています。

欧州も結合組織病治療市場において支配的な地域であるが、これは自己免疫疾患の罹患率の増加、強固なヘルスケアシステム、先進治療の普及に起因します。ドイツ、フランス、英国、イタリアのような国々は、関節リウマチやループスのような疾患に対する意識の高まりとともに、市場への主要な貢献国となっています。欧州連合（EU）の新薬承認に関する規制の枠組みは、公的ヘルスケア制度と相まって、革新的な治療法の普及と利用しやすさを促進しています。さらに、欧州は医学研究とバイオ医薬品の技術革新の中心地であり、数多くの企業が新しい生物製剤や治療法の開発に注力しています。主要製薬企業の存在感が強く、自己免疫疾患研究への投資も増加していることから、欧州の主要市場プレーヤーとしての地位はさらに揺るぎないものとなっています。

結合組織病治療市場 - 競合情勢：

結合組織病治療市場の競争力学は、技術革新と製品ポートフォリオの拡大に注力する大手製薬企業と新興バイオ医薬品企業の融合によって形成されています。AbbVie、Amgen、Boehringer Ingelheim、Bristol-Myers Squibb、F. Hoffmann-La Rocheなどの大手企業は、幅広い生物学的製剤と免疫抑制剤で市場を独占しており、治療の有効性と安全性を向上させるために研究開発に多額の投資を行っています。新規参入企業もまた、標的療法や個別化医療のアプローチで市場を前進させています。このような競合環境が絶え間ない技術革新を促進し、結合組織病患者にとってより効果的で利用しやすい治療法の開発を後押ししています。

目次

第1章 結合組織病治療市場の概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 結合組織病治療の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 結合組織病治療の産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 結合組織病治療市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 結合組織病治療市場情勢

  • 結合組織病治療市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 主要企業の分析
    • 新興企業の分析

第7章 結合組織病治療市場 - 疾患別

  • 概要
    • 疾患別セグメントシェア分析
    • 関節リウマチ（RA）
    • 全身性エリテマトーデス（SLE）
    • 強皮症
    • 多発性筋炎
    • 皮膚筋炎
    • シェーグレン症候群
    • 混合性結合組織病（MCTD）
    • 未分化結合組織疾患（UCTD）
    • その他の結合組織疾患

第8章 結合組織病治療市場 - 薬剤別

  • 概要
    • セグメントシェア分析 - 薬剤別
    • 医薬品
      • 非ステロイド性抗炎症薬（NSAID）
      • 疾患修飾性抗リウマチ薬（DMARD）
      • コルチコステロイド
      • その他の医薬品
    • バイオ医薬品
      • 生物学的製剤
      • TNF阻害剤
      • IL-6阻害剤
      • B細胞阻害剤
      • T細胞阻害剤
      • その他の生物学的製剤
      • バイオシミラー

第9章 結合組織病治療市場 - 流通チャネル別

  • 概要
    • セグメントシェア分析 - 流通チャネル別
    • 病院薬局
    • 小売薬局
    • オンライン薬局

第10章 結合組織病治療市場 - 地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋
    • 概要
    • アジア太平洋の主要メーカー
    • インド
    • 中国
    • 韓国
    • 日本
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析 - 結合組織病治療業界

  • 競合ダッシュボード
  • 企業プロファイル
    • AbbVie, Inc.
    • Amgen, Inc.
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • Johnson &Johnson Services, Inc.
    • Lily
    • Novartis AG
    • Pfizer Inc.
    • Regeneron Pharmaceuticals Inc.
    • UCB SA
    • その他

第12章 アナリストの全方位展望

目次
Product Code: ANV5227

REPORT HIGHLIGHT

Connective Tissue Disease Treatment Market size was valued at USD 24,169.10 Million in 2024, expanding at a CAGR of 5.89% from 2024 to 2032.

Connective tissue disease treatment involves managing autoimmune conditions that affect tissues like skin, joints, muscles, and organs. Treatment typically focuses on reducing inflammation, controlling immune system activity, and relieving symptoms. Common approaches include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, immunosuppressants, and disease-modifying antirheumatic drugs (DMARDs). Biologic therapies may be used in severe cases. Physical therapy and lifestyle modifications support mobility and overall health. Treatment is tailored to the specific disease, such as lupus, scleroderma, or rheumatoid arthritis, and varies based on severity and organ involvement. Regular monitoring and multidisciplinary care are essential to prevent complications and improve long-term outcomes.

Connective Tissue Disease Treatment Market- Market Dynamics

Rising Prevalence of Autoimmune Disorders

The growing incidence of autoimmune diseases such as rheumatoid arthritis, lupus, and scleroderma is a major driver for the connective tissue disease treatment market. As more individuals are diagnosed with these chronic conditions globally, the demand for effective treatment options continues to rise. Aging populations, increased awareness, and improved diagnostic capabilities contribute to earlier detection and treatment initiation. This surge in patient populations compels pharmaceutical companies to invest in research and development of novel therapies, including biologics and targeted immunosuppressants. Consequently, this trend is fueling market growth and expanding the availability of advanced therapeutic solutions.

Connective Tissue Disease Treatment Market- Key Insights

According to our research analyst, the global Connective Tissue Disease Treatment Market is expected to develop at a CAGR of approximately 5.89% between 2024-2032.

Segmented by Disease in 2023, the Rheumatoid Arthritis (RA) category dominated the market.

Based on Drug, the Biopharmaceuticals segment generated the most income in 2023.

On the basis of region, in 2023, North America was the region with the highest revenue.

Connective Tissue Disease Treatment Market- Segmentation Analysis:

The global Connective Tissue Disease Treatment Market is divided into three categories: Disease, Drug, Distribution Channel and Region.

The connective tissue disease treatment market is categorized by disease type into several key segments: Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Scleroderma, Polymyositis, Dermatomyositis, Sjogren's Syndrome, Mixed Connective Tissue Disease (MCTD), Undifferentiated Connective Tissue Disease (UCTD), and other connective tissue diseases. Each condition requires a tailored treatment approach, often involving immunosuppressants, biologics, and symptom management strategies. Among these, Rheumatoid Arthritis (RA) is the dominant segment due to its high prevalence and the significant impact it has on patients' quality of life. RA drives the majority of market demand, with ongoing advancements in biologic therapies and disease-modifying antirheumatic drugs (DMARDs) that offer improved efficacy and patient outcomes. The rising incidence of RA, combined with continuous innovation in treatment options, solidifies its leading position in the market.

The connective tissue disease treatment market is segmented by drug type into Pharmaceuticals and Biopharmaceuticals. Pharmaceuticals primarily include traditional drugs like nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and immunosuppressive medications that help control inflammation and manage symptoms. Biopharmaceuticals encompass biologic agents such as monoclonal antibodies, targeted therapies, and other advanced biologic treatments that aim to modify the disease's progression and immune system response. Among these, Biopharmaceuticals dominate the market due to their superior efficacy in treating complex autoimmune conditions. The rise of biologics, particularly in diseases like rheumatoid arthritis and lupus, has revolutionized treatment paradigms, offering patients more personalized and effective therapies. Biopharmaceuticals continue to drive market growth, supported by ongoing research, new drug approvals, and better patient outcomes.

Connective Tissue Disease Treatment Market- Geographical Insights

Geographically, the Connective Tissue Disease Treatment Market is distributed throughout North America, Asia Pacific, Latin America, Europe, the Middle East, and Africa. These regions are further divided based on the nations bringing in business.

North America is the dominant region in the connective tissue disease treatment market, driven by the high prevalence of autoimmune diseases like rheumatoid arthritis, lupus, and scleroderma. The United States, in particular, holds a significant market share due to advanced healthcare infrastructure, early diagnosis, and an aging population, which is more susceptible to these diseases. The region also benefits from the presence of major pharmaceutical and biopharmaceutical companies, which invest heavily in research and development of new treatments. Additionally, favorable reimbursement policies and improved awareness around autoimmune disorders contribute to the market's growth. The demand for innovative biologics and immunosuppressants further accelerates the region's dominance, making it a leader in both market size and therapeutic advancements.

Europe is another dominant region in the connective tissue disease treatment market, owing to the increasing incidence of autoimmune diseases, robust healthcare systems, and widespread availability of advanced treatments. Countries like Germany, France, the United Kingdom, and Italy are key contributors to the market, with growing awareness about diseases such as rheumatoid arthritis and lupus. The European Union's regulatory framework for approving new drugs, combined with supportive public healthcare systems, promotes the availability and accessibility of innovative treatments. Additionally, Europe is a hub for medical research and biopharmaceutical innovation, with numerous companies focused on developing new biologics and therapies. The strong presence of leading pharmaceutical companies and growing investment in autoimmune disease research further solidify Europe's position as a major market player.

Connective Tissue Disease Treatment Market- Competitive Landscape:

The competitive dynamics of the Connective Tissue Disease Treatment Market are shaped by a blend of established pharmaceutical giants and emerging biopharmaceutical companies, all focused on innovation and expanding their product portfolios. Major players such as AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, and F. Hoffmann-La Roche dominate the market with a wide range of biologics and immunosuppressants, heavily investing in research and development to improve treatment efficacy and safety. New entrants are also advancing the market with targeted therapies and personalized medicine approaches. This competitive environment fosters continuous innovation, driving the development of more effective and accessible treatments for patients with connective tissue diseases.

Recent Developments:

In February 2025, AbbVie intensified its focus on autoimmune diseases by acquiring Celsius Therapeutics for $250 million. Celsius is developing CEL383, an oral antibody targeting TREM1, a gene associated with inflammatory bowel disease (IBD). This acquisition complements AbbVie's strategy to diversify its immunology pipeline, particularly as it shifts from Humira to newer therapies like Skyrizi and Rinvoq.

In June 2024, Pfizer launched a new biologic therapy aimed at improving outcomes for patients with lupus. This development underscores Pfizer's commitment to addressing unmet needs in autoimmune diseases. The therapy is part of Pfizer's broader strategy to enhance its portfolio in immunology and autoimmune disease treatments.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CONNECTIVE TISSUE DISEASE TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AbbVie, Inc.
  • Amgen, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Lily
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • UCB S.A.
  • Others

GLOBAL CONNECTIVE TISSUE DISEASE TREATMENT MARKET, BY DISEASE - MARKET ANALYSIS, 2019 - 2032

  • Rheumatoid Arthritis (RA)
  • Systemic Lupus Erythematosus (SLE)
  • Scleroderma
  • Polymyositis
  • Dermatomyositis
  • Sjogren's Syndrome
  • Mixed Connective Tissue Disease (MCTD)
  • Undifferentiated Connective Tissue Disease (UCTD)
  • Other connective tissue diseases

GLOBAL CONNECTIVE TISSUE DISEASE TREATMENT MARKET, BY DRUG - MARKET ANALYSIS, 2019 - 2032

  • Pharmaceuticals
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
  • Corticosteroids
  • Other Pharmaceuticals
  • Biopharmaceuticals
  • Biologics
  • TNF Inhibitors
  • IL-6 Inhibitors
  • B-cell Inhibitors
  • T-cell Inhibitors
  • Other Biologics
  • Biosimilars

GLOBAL CONNECTIVE TISSUE DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL INDUSTRY - MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL CONNECTIVE TISSUE DISEASE TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Connective Tissue Disease Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Connective Tissue Disease Treatment Market Snippet by Disease
    • 2.1.2. Connective Tissue Disease Treatment Market Snippet by Drug
    • 2.1.3. Connective Tissue Disease Treatment Market Snippet by Distribution Channel
    • 2.1.4. Connective Tissue Disease Treatment Market Snippet by Country
    • 2.1.5. Connective Tissue Disease Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Connective Tissue Disease Treatment Key Market Trends

  • 3.1. Connective Tissue Disease Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Connective Tissue Disease Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Connective Tissue Disease Treatment Market Opportunities
  • 3.4. Connective Tissue Disease Treatment Market Future Trends

4. Connective Tissue Disease Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Connective Tissue Disease Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Connective Tissue Disease Treatment Market Landscape

  • 6.1. Connective Tissue Disease Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Connective Tissue Disease Treatment Market - By Disease

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Disease, 2023 & 2032 (%)
    • 7.1.2. Rheumatoid Arthritis (RA)
    • 7.1.3. Systemic Lupus Erythematosus (SLE)
    • 7.1.4. Scleroderma
    • 7.1.5. Polymyositis
    • 7.1.6. Dermatomyositis
    • 7.1.7. Sjogren's Syndrome
    • 7.1.8. Mixed Connective Tissue Disease (MCTD)
    • 7.1.9. Undifferentiated Connective Tissue Disease (UCTD)
    • 7.1.10. Other connective tissue diseases

8. Connective Tissue Disease Treatment Market - By Drug

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug, 2023 & 2032 (%)
    • 8.1.2. Pharmaceuticals
      • 8.1.2.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
      • 8.1.2.2. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
      • 8.1.2.3. Corticosteroids
      • 8.1.2.4. Other Pharmaceuticals
    • 8.1.3. Biopharmaceuticals
      • 8.1.3.1. Biologics
      • 8.1.3.1.1. TNF Inhibitors
      • 8.1.3.1.2. IL-6 Inhibitors
      • 8.1.3.1.3. B-cell Inhibitors
      • 8.1.3.1.4. T-cell Inhibitors
      • 8.1.3.1.5. Other Biologics
      • 8.1.3.2. Biosimilars

9. Connective Tissue Disease Treatment Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Online Pharmacies

10. Connective Tissue Disease Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Connective Tissue Disease Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Connective Tissue Disease Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. France
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. France Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.8.4. France Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.8.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. Italy
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. Italy Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.9.4. Italy Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.9.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. Spain
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. United Kingdom Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.10.4. United Kingdom Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.10.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. United Kingdom
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. United Kingdom Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.11.4. United Kingdom Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.11.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Russia
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Russia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Russia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Netherlands
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Netherlands Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Netherlands Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Sweden
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Sweden Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Sweden Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.2. Poland Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Connective Tissue Disease Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. South Korea
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. South Korea Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.9.4. South Korea Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.9.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. Japan
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. Japan Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.10.4. Japan Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.10.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Connective Tissue Disease Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Connective Tissue Disease Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Connective Tissue Disease Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. AbbVie, Inc.
    • 11.2.2. Amgen, Inc.
    • 11.2.3. Boehringer Ingelheim International GmbH
    • 11.2.4. Bristol-Myers Squibb Company
    • 11.2.5. F. Hoffmann-La Roche Ltd.
    • 11.2.6. Johnson & Johnson Services, Inc.
    • 11.2.7. Lily
    • 11.2.8. Novartis AG
    • 11.2.9. Pfizer Inc.
    • 11.2.10. Regeneron Pharmaceuticals Inc.
    • 11.2.11. UCB S.A.
    • 11.2.12. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us